Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate SARS-CoV-2 infection models. Here, we investigated the immunogenicity, protective efficacy, and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a moderate disease Syrian hamster challenge model, using the currently most prevalent G614 spike SARS-CoV-2 variant. Vaccine doses of 1 × 109 and 1 × 1010 VP elicited substantial neutralizing antibodies titers and completely protected over 80% of SARS-CoV-2 inoculated Syrian hamsters from lung infection and pneumonia but not upper respiratory tract infection. A second vaccine dose further increased neutralizing antibody titers that was associated with decreased infectious viral load in the upper respiratory tract after SARS-CoV-2 challenge. Suboptimal non-protective immune responses elicited by low-dose A26.COV2.S vaccination did not exacerbate respiratory disease in SARS-CoV-2-inoculated Syrian hamsters with breakthrough infection. In addition, dosing down the vaccine allowed to establish that binding and neutralizing antibody titers correlate with lower respiratory tract protection probability. Overall, these preclinical data confirm efficacy of a one-dose vaccine regimen with Ad26.COV2.S in this G614 spike SARS-CoV-2 virus variant Syrian hamster model, show the added benefit of a second vaccine dose, and demonstrate that there are no signs of VAERD under conditions of suboptimal immunity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
NPJ vaccines - 6(2021), 1 vom: 19. März, Seite 39 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van der Lubbe, Joan E M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 13.04.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s41541-021-00301-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322984343 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322984343 | ||
| 003 | DE-627 | ||
| 005 | 20231225183209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41541-021-00301-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM322984343 | ||
| 035 | |a (NLM)33741993 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van der Lubbe, Joan E M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.04.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate SARS-CoV-2 infection models. Here, we investigated the immunogenicity, protective efficacy, and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a moderate disease Syrian hamster challenge model, using the currently most prevalent G614 spike SARS-CoV-2 variant. Vaccine doses of 1 × 109 and 1 × 1010 VP elicited substantial neutralizing antibodies titers and completely protected over 80% of SARS-CoV-2 inoculated Syrian hamsters from lung infection and pneumonia but not upper respiratory tract infection. A second vaccine dose further increased neutralizing antibody titers that was associated with decreased infectious viral load in the upper respiratory tract after SARS-CoV-2 challenge. Suboptimal non-protective immune responses elicited by low-dose A26.COV2.S vaccination did not exacerbate respiratory disease in SARS-CoV-2-inoculated Syrian hamsters with breakthrough infection. In addition, dosing down the vaccine allowed to establish that binding and neutralizing antibody titers correlate with lower respiratory tract protection probability. Overall, these preclinical data confirm efficacy of a one-dose vaccine regimen with Ad26.COV2.S in this G614 spike SARS-CoV-2 virus variant Syrian hamster model, show the added benefit of a second vaccine dose, and demonstrate that there are no signs of VAERD under conditions of suboptimal immunity | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Rosendahl Huber, Sietske K |e verfasserin |4 aut | |
| 700 | 1 | |a Vijayan, Aneesh |e verfasserin |4 aut | |
| 700 | 1 | |a Dekking, Liesbeth |e verfasserin |4 aut | |
| 700 | 1 | |a van Huizen, Ella |e verfasserin |4 aut | |
| 700 | 1 | |a Vreugdenhil, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Baert, Miranda R M |e verfasserin |4 aut | |
| 700 | 1 | |a Feddes-de Boer, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Izquierdo Gil, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a van Heerden, Marjolein |e verfasserin |4 aut | |
| 700 | 1 | |a Dalebout, Tim J |e verfasserin |4 aut | |
| 700 | 1 | |a Myeni, Sebenzile K |e verfasserin |4 aut | |
| 700 | 1 | |a Kikkert, Marjolein |e verfasserin |4 aut | |
| 700 | 1 | |a Snijder, Eric J |e verfasserin |4 aut | |
| 700 | 1 | |a de Waal, Leon |e verfasserin |4 aut | |
| 700 | 1 | |a Stittelaar, Koert J |e verfasserin |4 aut | |
| 700 | 1 | |a Tolboom, Jeroen T B M |e verfasserin |4 aut | |
| 700 | 1 | |a Serroyen, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Muchene, Leacky |e verfasserin |4 aut | |
| 700 | 1 | |a van der Fits, Leslie |e verfasserin |4 aut | |
| 700 | 1 | |a Rutten, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Langedijk, Johannes P M |e verfasserin |4 aut | |
| 700 | 1 | |a Barouch, Dan H |e verfasserin |4 aut | |
| 700 | 1 | |a Schuitemaker, Hanneke |e verfasserin |4 aut | |
| 700 | 1 | |a Zahn, Roland C |e verfasserin |4 aut | |
| 700 | 1 | |a Wegmann, Frank |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NPJ vaccines |d 2016 |g 6(2021), 1 vom: 19. März, Seite 39 |w (DE-627)NLM273825623 |x 2059-0105 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2021 |g number:1 |g day:19 |g month:03 |g pages:39 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41541-021-00301-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2021 |e 1 |b 19 |c 03 |h 39 | ||